Appointment of Nominated Adviser and Broker

RNS Number : 3744X
Venture Life Group PLC
19 November 2014


Venture Life Group plc

("Venture Life" or "the Company")


Appointment of Nominated Adviser and Broker


Bracknell, UK - 19 November 2014: Venture Life Group plc (AIM: VLG), the international consumer products group addressing the self-care needs of the ageing population, announces that it has appointed Panmure Gordon (UK) Limited as its Nominated Adviser and sole Broker with immediate effect.




For further information please contact:

Venture Life Group PLC

James Hunter, Chief Financial Officer                                                    +44 (0) 1344 742 870


Panmure Gordon (UK) Limited                 
Freddy Crossley / Duncan Monteith                                       
                +44 (0) 20 7886 2500
Corporate Finance

Tom Salvesen
Corporate Broking                                                                                                          


Square1 Consulting

David Bick                                                                                                           +44 (0) 20 7929 5599

Mark Longson                                                                                                   


About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its topical development and manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 50 countries and currently include:

·     food supplements to maintain brain function and memory;

·     dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

·     medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.


This information is provided by RNS
The company news service from the London Stock Exchange
UK 100

Latest directors dealings